AC Immune (NASDAQ:ACIU) Stock Picked Up by Analysts at HC Wainwright

Equities research analysts at HC Wainwright assumed coverage on shares of AC Immune (NASDAQ:ACIU) in a research report issued on Thursday, Zacks reports. The firm set a “strong-buy” rating on the stock. HC Wainwright also issued estimates for AC Immune’s Q1 2027 earnings at $0.06 EPS, Q2 2027 earnings at $0.06 EPS, Q3 2027 earnings at $0.14 EPS and Q4 2027 earnings at $0.17 EPS.

Other research analysts have also issued research reports about the company. Zacks Research lowered AC Immune from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 28th. Weiss Ratings raised AC Immune from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. Finally, BTIG Research reiterated a “buy” rating and issued a $8.00 target price on shares of AC Immune in a research report on Wednesday, September 23rd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.50.

AC Immune Trading Up 5.7%

Shares of NASDAQ:ACIU traded up $0.12 during midday trading on Thursday, reaching $2.23. 180,406 shares of the company were exchanged, compared to its average volume of 198,938. The business’s fifty day moving average is $2.54 and its two-hundred day moving average is $2.70. AC Immune has a one year low of $2.02 and a one year high of $3.90. The stock has a market cap of $226.95 million, a PE ratio of -4.46 and a beta of 1.64.

AC Immune (NASDAQ:ACIU) last posted its earnings results on Wednesday, November 4th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02. The company had revenue of $3.88 million during the quarter, compared to analysts’ expectations of $1.62 million. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%.

Institutional Investors Weigh In On AC Immune

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership lifted its holdings in shares of AC Immune by 8.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock worth $1,116,000 after acquiring an additional 30,035 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in AC Immune by 82.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after purchasing an additional 176,701 shares during the last quarter. Finally, AXQ Capital LP bought a new position in AC Immune during the 2nd quarter valued at about $25,000. Hedge funds and other institutional investors own 51.36% of the company’s stock.

More AC Immune News

Here are the key news stories impacting AC Immune this week:

• Positive Sentiment: HC Wainwright assigned AC Immune a Strong Buy rating and forecast a shift from a projected 2026 loss of $0.54 per share to earnings of $0.43 in 2027, rising to $1.73 by 2030. Those longer-term profit expectations may support investor optimism, although they are analyst forecasts rather than company guidance. HC Wainwright recommendations
• Neutral Sentiment: The multiple reports largely repeat the same HC Wainwright estimates; they do not describe a new company announcement or a change to the analyst’s outlook.
• Negative Sentiment: The forecast still anticipates a per-share loss in 2026, and the projected move to profitability depends on future performance, so execution risk remains.

About AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.